Contract Development and Manufacturing Organization (CDMO) Market to hit US$ 280.07 billion by 2033, (CAGR 7.4%)

Contract Development and Manufacturing (CDMO) Market Intelligence Report 2025-2033

AUSTIN, TX, UNITED STATES, December 19, 2025 /EINPresswire.com/ -- Market Size and Growth

According to industry analysis, the CDMO market achieved a valuation of US$ 150.19 billion in 2024 and is anticipated to grow to US$ 280.07 billion by 2033, driven by increased outsourcing across pharma and biotech, at a (CAGR 7.4%) from 2025 to 2033.

The market is driven by pharmaceutical and biotechnology companies increasingly outsourcing drug development and manufacturing to reduce capital expenditure, accelerate time-to-market, and comply with stringent regulatory requirements. CDMOs offer integrated services spanning drug discovery support, formulation development, clinical manufacturing, commercial-scale production, and packaging, making them strategic partners across the drug lifecycle.

Rising biologics, cell & gene therapies, and complex injectables, combined with capacity constraints at pharma companies, are accelerating global CDMO adoption.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):– https://www.datamintelligence.com/download-sample/contract-development-and-manufacturing-market

Growth Drivers

1. Over 65% of global pharmaceutical companies outsourced at least one stage of drug development or manufacturing in 2024

2. Biologics and advanced therapies accounted for more than 45% of new CDMO contracts globally

3. Pharmaceutical R&D spending surpassed USD 250 billion in 2024, boosting demand for external development expertise

4. FDA and EMA approvals for outsourced-manufactured drugs increased by 30% since 2021

5. CDMO partnerships reduce drug development timelines by 20–30%, improving commercialization success rates

Market Segmentation Analysis

By Service Type

The CDMO market is segmented into Contract Development and Contract Manufacturing.

Contract Manufacturing dominates with 62% market share (USD 123.1 billion in 2024), driven by demand for commercial-scale production of small molecules, biologics, and injectables. It is projected to reach USD$ 290.6 billion by 2032.

Contract Development accounts for 38% (USD$ 75.5 billion) and is growing rapidly due to increasing early-stage outsourcing for formulation, analytical testing, and clinical trial material production.

By Product Type

Small Molecules lead with 54% market share (USD$ 107.27 billion in 2024), supported by strong demand for generic drugs and oral solid dosage forms.

Biologics & Biosimilars represent 34% (USD$ 67.5 billion) and are expected to grow at the fastest CAGR, driven by monoclonal antibodies, vaccines, and recombinant proteins.

Advanced Therapies (Cell & Gene Therapy) account for the remaining 12% and are expanding rapidly due to pipeline growth and limited in-house capabilities.

By End User

Pharmaceutical Companies held 58% market share, driven by lifecycle management and cost optimization strategies.

Biotechnology Companies accounted for 34%, relying heavily on CDMOs for clinical and commercial production.

Academic & Research Institutes contributed 8%, mainly for early-stage development and pilot manufacturing.

Request for Customized Sample Report as per Your Business Requirement:- https://www.datamintelligence.com/customize/contract-development-and-manufacturing-market

Regional Insights

United States

The U.S. CDMO market was valued at USD$ 74.74 billion in 2024 and is projected to reach USD 172.27 billion by 2032, growing at 10.91% CAGR.
Strong FDA regulatory framework supports outsourced manufacturing

High concentration of biologics and gene therapy developers

Over 70% of U.S.-based biotech firms rely on CDMOs for clinical-stage production

Europe

Europe accounted for 26% of global CDMO revenue in 2024.

Germany, Switzerland, and the UK lead in biologics and sterile manufacturing

EMA-approved facilities and skilled workforce strengthen outsourcing confidence

Increasing investments in fill-finish and vaccine manufacturing

Asia-Pacific

Asia-Pacific is expected to register the fastest CAGR (12.6%) through 2032.

China and India are major hubs for API and generic drug manufacturing

Japan and South Korea lead in high-value biologics manufacturing

Cost advantages and expanding regulatory compliance drive regional growth

Competitive Landscape

According to DataM Intelligence, the CDMO market is moderately fragmented, with global leaders expanding capacity through acquisitions and technology upgrades.

Key Players

Lonza Group | Catalent Inc. | Thermo Fisher Scientific | Samsung Biologics | WuXi AppTec | Siegfried Holding | Piramal Pharma Solutions | Aenova Group | Baxter BioPharma Solutions | Recipharm AB | Jubilant Pharmova Limited | Boehringer Ingelheim International GmbH | IQVIA | Syneos Health | Parexel International (MA) Corporation | Curia Global, Inc. | NextPharma Technologies

Key Highlights

1. Lonza Group expanded biologics capacity with USD$ 1.2 billion investment

2. Samsung Biologics surpassed 700,000 liters of biologics manufacturing capacity

3. Thermo Fisher Scientific strengthened integrated CDMO services through acquisitions

4. WuXi AppTec expanded cell and gene therapy manufacturing footprint globally

Recent Developments

1. Lonza announced a new large-scale mammalian cell facility

2. Samsung Biologics signed multi-year contracts with top 10 global pharma firms

3. Catalent expanded sterile injectables capacity in Europe

4. Piramal Pharma Solutions invested in peptide and ADC manufacturing

Buy This Report
Year-End Offer:
Buy 1 Report – 30% OFF
Buy 2 Reports – 50% OFF each:- https://www.datamintelligence.com/buy-now-page?report=contract-development-and-manufacturing-market

Key Forecast Indicators

1. Biologics CDMO segment to exceed USD 170 billion by 2032

2. Clinical-stage outsourcing to grow faster than commercial manufacturing

3. Cell & gene therapy CDMO services to grow at >18% CAGR

4. Asia-Pacific to remain the fastest-growing manufacturing hub

5. Integrated end-to-end CDMO models to dominate future contracts

Conclusion

The Global Contract Development and Manufacturing Organization (CDMO) Market is evolving into a strategic backbone of the pharmaceutical and biotechnology industries, CDMOs are enabling faster innovation, scalable production, and regulatory compliance across the drug lifecycle.

According to DataM Intelligence, leading players such as Lonza, Samsung Biologics, Thermo Fisher Scientific, and WuXi AppTec are shaping the future of outsourced pharmaceutical manufacturing through capacity expansion, advanced technologies, and integrated service offerings. As biologics, personalized medicine, and advanced therapies continue to surge, CDMOs will remain critical partners in global healthcare innovation.

Related Reports

Pharmaceutical Contract Development and Manufacturing Market

India Contract Development and Manufacturing (CDMO) Market

Sai Kiran
DataM Intelligence 4market Research LLP
+1 877-441-4866
sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
YouTube
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.